Following three weeks of extracorporeal lung support for acute respiratory distress syndrome, a 15-year-old male underwent bilateral lung transplantation. This procedure was complicated by massive postoperative haemorrhage. The administration of recombinant activated Factor VII was associated with improved haemostasis. However, development of cardiac tamponade soon after injection required emergency exploration and evacuation of a large mediastinal clot.
Replacement of depleted coagulation factors in patients receiving massive blood transfusion is achieved by fractionated blood products such as platelets, fresh frozen plasma or cryoprecipitate. Despite fractionated blood transfusion, relative and absolute deficiencies of specific coagulation factors may result 1, 2 . Recombinant techniques have been developed for replacement of factors in patients with specific deficiencies (e.g., haemophilia). The administration of these recombinant factors, specifically recombinant activated factor VII (rFVIIa), has been successfully described in post-surgical and trauma patients at risk of, or receiving, massive blood transfusion. 3, 4, 5 We present a case of the administration of rFVIIa in a patient with exsanguinating haemorrhage following lung transplantation.
CASE REPORT
A 15-year-old male was transferred to The St George Hospital for consideration for extracorporeal lung support seven days after the development of severe acute respiratory distress syndrome following post-influenza staphylococcal pneumonitis. Despite pressure-and volume-limited mechanical ventilation, inhaled nitric oxide and pulsed methylprednisolone, the patient's P a O 2 /FiO 2 ratio was 50, and pH/P a CO 2 7.01/102 mmHg. A veno-venous extracorporeal circuit via left internal jugular and right femoral veins was established and extracorporeal membrane oxygenation and carbon dioxide removal was commenced. Low-frequency, low-tidal volume mechanical ventilation with 12 cm H 2 O positive endexpiratory pressure was administered simultaneously. Extracorporeal circuit patency was maintained using a heparin-bonded circuit and low-dose intravenous heparin infusion to maintain activated clotting time at 150-175 s. Institution of extracorporeal lung support resulted in a prompt improvement in gaseous exchange (P a O 2 /FiO 2 135) and acid-base status (pH 7.38, P a CO 2 =45 mmHg).
This supportive strategy continued for the next 29 days, during which time no other acute organ failure developed. During this period, he maintained normal coagulation apart from persistent thrombocytopenia (40-90x10 9 /l) requiring intermittent platelet transfusions. The patient remained fully dependent on extracorporeal lung support to maintain gaseous exchange, due to non-resolution of intense bilateral pulmonary infiltrates and persistent poor lung compliance ( Figure 1a ). Given the inability to wean extracorporeal lung support, the patient was listed for urgent bilateral lung transplantation, which was performed on day 29.
The procedure was complicated by severe bleeding requiring massive blood transfusion (>20 units packed red blood cells). Bleeding was primarily due to separation of densely adherent, markedly inflamed pleural surfaces that resulted in a large raw surface. The resultant dilutional coagulopathy was due to continued bleeding and the use of a cell-saver device. Despite clotting factor replacement, the patient developed a severe dilutional and consumptive coagulopathy ( Table 1 ). The chest was closed after lung implantation and the patient transferred to the intensive care unit ( Figure 1b ).
The immediate postoperative course was complicated by continuous bleeding at a rate of between 500 and 1000 ml/h via his chest drains. During the following 12 hours, drainage blood was collected, washed and reinfused via the cell-saver device. Further blood products including packed cells (20 units), platelets (35 units), fresh frozen plasma (45 units) and cryoprecipitate (40 units) were administered. The patient remained haemodynamically stable throughout this period, responded to intravascular volume replacement and maintained normal renal function. He was ventilated using standard volume-limited mechanical ventilation and maintained normal gaseous exchange.
Re-operation for surgical haemostasis was considered throughout this period, but deferred due to the severe coagulopathy. By 12 hours postoperatively, current medical therapy was not achieving adequate haemostasis, despite marginal improvement in some coagulation studies (Table 1) .
A factor VIII assay was performed, demonstrating a level of 51% (normal 50-150%). On the basis of this result and the refractory coagulopathy, a course of rFVIIa (one dose of 90 µg/kg) was administered.
Although there was no immediate cessation of bleeding following the injection, the patient developed increased right heart pressures and systemic hypotension within 30 minutes. This was associated with deterioration in gaseous exchange, and chest X-ray demonstrated an increased cardiac silhouette, suggestive of cardiac tamponade (Figure 2a ). The patient was promptly returned to theatre.
At re-operation, 3 evacuated from the anterior mediastinum and pericardial space, with prompt return of haemodynamic stability. The surgeons noted that there was improved blood clotting within the chest cavity, requiring minimal surgical intervention, compared to the end of the initial operation.
The patient was transferred back to the intensive care unit in a haemodynamically stable condition with minimal bleeding from the chest drains. Respiratory function was normal (Figure 2b) . A second dose of rFVIIa (90 µg/kg) was administered postoperatively, with no further bleeding or systemic compromise. Coagulation studies normalized within 24 hours of the first procedure ( Table 1) .
The patient remained in intensive care for a further two weeks during which he was successfully weaned from mechanical ventilation. He developed no organ failure and was eventually discharged home after four weeks. At nine months post-transplant, he was doing well.
DISCUSSION
This case report highlights the use of rFVIIa as an adjunct for medical correction of severe coagulopathy in a complex surgical patient.
Prolonged preoperative heparinization, and thrombocytopenia associated with the extracorporeal circuit 6 , predisposed the patient to intraoperative bleeding. During the procedure, the dissection of the diseased lung and pleural surface in a fully anticoagulated patient resulted in massive haemorrhage. The use of a cell-saver device and reinfusion of blood is associated with dilution of endogenous clotting factors, specifically fibrinogen, factors V, VIII, X 7 , reduction in platelet numbers and function 8 and activation of cellular and humoral inflammatory mediators 9 .
The decision to close the chest in an actively bleeding patient was a calculated one, with the expectation that the bleeding would arrest following restoration of normothermia and continued blood and component transfusion in the intensive care unit. Ideally, fresh, whole blood would have been the replacement transfusion of choice. However, this was not available, and is an infrequent resource in modern practice. Whilst blood component therapy was assiduously administered throughout the perioperative period, deficiencies of clotting factors in such a patient were inevitable, specifically factors VII and VIII.
Factor VII is a vitamin K-dependent pro-coagulant protein that is synthetized in the liver. Initiation of haemostasis involves formation of a complex between tissue factor and FVIIa following injury. Tissue factor is exposed following damage to subendothelial layers of the vessel wall. The resultant tissue factor/FVIIa complex activates factors V, VIII, IX, X, XI and platelets leading to production of thrombin and clot formation. Factor VII may induce haemostasis in the absence of factors VIII and IX. In vitro studies have demonstrated that recombinant factor VII binds to activated platelet surfaces and, independently of tissue factor, may induce the thrombin burst required for haemostasis 10 .
Advances in biotechnology and plasma protein purification and the requirement to minimize the risk b a of viral transmission have resulted in the development of recombinant human plasma proteins. Recombinant activated factor VII has been in use since 1988, particularly in haemophiliac patients with inhibitors. The indications for its use have expanded to include a variety of congenital and acquired coagulation disorders such as factor VII, X and XI deficiencies, warfarin overdose 11 , cirrhosis 12 , uraemia 13 , qualitative and quantitative platelet disorders 14 . The administration of factor VII alone may be beneficial in patients with deficient factor levels due to dilutional or consumptive coagulopathies. Recently, recombinant factor VII has been successfully used in intractable surgical bleeding following cardiac surgery 15 , liver resection and transplantation 16 , prostatectomy 17 and traumatic bleeding 18 .
The decision to administer rFVIIa in this patient was based on the rate of blood transfusion required and refractory dilutional coagulopathy. Specifically, a reduced factor VIII level in the presence of a deteriorating coagulopathy was used as a surrogate index of factor VII levels, which we were unable to measure in this patient. The use of recombinant factor VII in this patient was associated with haemostasis, which only became macroscopically apparent at re-operation. The resultant clot formation in the mediastinum and pericardial space was associated with direct pressure effects and cardiac tamponade. This was an important consequence of recombinant factor VII and posed an additional lifethreatening complication.
The association of rFVIIa and clinically significant clot formation has not been previously described. In an animal study, Martinowitz failed to demonstrate any pathological evidence of macro-or microscopic thrombus formation in a porcine liver trauma model in whom rFVIIa significantly reduced haemorrhage 19 . In a series of seven massively bleeding patients treated with rFVIIa, no clinical evidence of thromboembolism was observed 18 .
Recombinant factor VII is an expensive drugwholesale acquisition cost is US$0.81 per µg, translating to AUD$8100 in a 70 kg person per dose 20 . A decision to administer this drug has to be made considering this expense, restricting its use to patients who are most likely to benefit.
In conclusion, the administration of rFVIIa resulted in progressive haemostasis in a patient with a life-threatening, multifactorial postoperative haemorrhage. Whilst haemostasis reduced active bleeding, the formation of large clots in the anterior mediastinum and pericardial space resulted in cardiac tamponade, which responded to evacuation.
The prompt return of coagulation studies to normal in the postoperative period may be attributable to the central action of factor VII in the coagulation cascade, once surgical haemostasis was obtained. Further definitive studies of this effective but expensive agent are warranted.
